|  |
| --- |
| **Medication Assisted Treatment (MAT) Commission**  |
| **Meeting agenda** | **Commission charge(s) discussed during meeting** |
| **March 19, 2019****Agenda** **1. Welcome and Acceptance of Minutes**  **2. Hilary Smith Connery, MD, PhD – McLean Hospital** **3. Consumer Panel** **4. DPH Overview of MAT Barriers** | **The Commission must:*** create aggregate demographic and geographic profiles of individuals who use medication-assisted treatment;
* examine the availability of and barriers to accessing medication-assisted treatment, including federal, state and local laws and regulations;
* determine the current utilization of, and projected need for, medication-assisted treatment in inpatient and outpatient settings, including, but not limited to, inpatient and residential substance use treatment facilities, inpatient psychiatric settings, pharmacy settings, mobile settings and primary care settings;
* identify ways to expand access to medication-assisted treatment in both inpatient and outpatient settings;
* identify ways to encourage practitioners to seek waivers to administer buprenorphine to treat patients with opioid use disorder;
* study the availability of and concurrent use of behavioral health therapy for individuals receiving medication-assisted treatment;
 |
| **January 24, 2019****Agenda**1. **Welcome and Introductions**
2. **Swearing in –Governor’s Office**
3. **Presentation on Open Meeting Law**
4. **Presentation on Code of Ethics**

**5. Presentation of Medication Assisted Treatment**  | **The Commission must:*** create aggregate demographic and geographic profiles of individuals who use medication-assisted treatment;
* examine the availability of and barriers to accessing medication-assisted treatment, including federal, state and local laws and regulations;
* determine the current utilization of, and projected need for, medication-assisted treatment in inpatient and outpatient settings, including, but not limited to, inpatient and residential substance use treatment facilities, inpatient psychiatric settings, pharmacy settings, mobile settings and primary care settings;
* identify ways to expand access to medication-assisted treatment in both inpatient and outpatient settings;
* identify ways to encourage practitioners to seek waivers to administer buprenorphine to treat patients with opioid use disorder;
* study the availability of and concurrent use of behavioral health therapy for individuals receiving medication-assisted treatment;
 |
| **Upcoming Meeting dates:** March 19, 1-3pm; May 21, 1-3pm; June 26, 1-3pm; July 30, 1-3pm**.** All meetings to be held in the Public Health Council (PHC) 250 Washington Street Boston MA  |
| **Commission Website:** [**https://www.mass.gov/orgs/medication-assisted-treatment-mat-commission**](https://www.mass.gov/orgs/medication-assisted-treatment-mat-commission)**Commission Email**: MAT.Commission@state.ma.us |
| **August 9, 2019 –** Submission of Commission’s findings and recommendations to the Legislature |